Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Chokri Ben Lamine: Anticoagulation Switching Pearls
AI generated
Apr 8, 2026, 14:17

Chokri Ben Lamine: Anticoagulation Switching Pearls

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Anticoagulation Switching Pearls (LMWH to Warfarin to DOAC)

LMWH to Warfarin – Overlap is mandatory:

  • At least 5 days and INR at least 2 for 24–48 hours
  • Prevent early hypercoagulability (decreased Protein C)

Start warfarin at 2–5 mg, adjust according to INR

Stop LMWH only when INR is stable and therapeutic

LMWH and DOAC

  • Switching from LMWH to DOAC: Start DOAC at the time of the next LMWH dose; no overlap
  • Switching from DOAC to LMWH: Start LMWH at the time of the next DOAC dose; no overlap

Warfarin to DOAC

  • If INR is less than 2, start DOAC immediately
  • If INR is 2 to 2.5, start on the same day
  • If INR is greater than 2.5, delay

DOAC to Warfarin

  • Overlap DOAC with warfarin
  • Stop DOAC once INR is therapeutic

DOAC VTE Dosing in Adults

Apixaban

  • Acute VTE: 10 mg BID for 7 days
  • Then 5 mg BID
  • Extended 2.5 mg BID
  • Least bleeding risk, preferred in many hematology patients

Rivaroxaban

  • Acute VTE: 15 mg BID for 21 days
  • Then 20 mg once daily
  • Extended 10 mg once daily
  • Take with food

Edoxaban

  • Requires lead-in LMWH for 5 to 10 days
  • Then 60 mg once daily
  • Reduce to 30 mg if weight 60 kg or less or CrCl 15 to 50

Dabigatran

  • Requires LMWH lead-in for 5 to 10 days
  • Then 150 mg BID
  • Avoid if CrCl less than 30
  • Higher gastrointestinal side effects

Key Clinical Pearls

  • Only dabigatran and edoxaban need LMWH lead-in
  • Apixaban and rivaroxaban follow a single-drug approach

Cancer-associated VTE

  • DOAC such as apixaban or rivaroxaban preferred
  • Use LMWH if gastrointestinal or genitourinary bleeding risk

APS triple positive

  • Avoid DOAC; use warfarin

Renal failure

  • Prefer warfarin if severe CKD

Drug interactions

  • DOAC affected by P-gp and CYP3A4 inhibitors such as azole, chemotherapy, tyrosine kinase inhibitors

Bridging rule

  • Warfarin requires overlap
  • DOAC requires timing switch with no overlap.”

Stay updated with Hemostasis Today.

Apixaban Chokri Ben Lamine CKD DOAC edoxaban Health Hematology Hemostasis Hemostasis News Hemostasis Today LMWH Medicine Rivaroxaban VTE Warfarin
NewsFeed